Guo, Jianxia <br/><br/>
Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice.  [electronic resource] 

 -  Cancer chemotherapy and pharmacology  Mar 2009 
 - 615-25 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>1432-0843 
<br/><br/><label>Standard No.: </label>10.1007/s00280-008-0774-y  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Basic Helix-Loop-Helix Leucine Zipper Transcription Factors--antagonists & inhibitors<br/>Cell Proliferation--drug effects<br/>Chromatography, High Pressure Liquid<br/>Chromatography, Liquid<br/>Dimerization<br/>Female<br/>Humans<br/>Male<br/>Mice<br/>Mice, SCID<br/>Prostatic Neoplasms--drug therapy<br/>Proto-Oncogene Proteins c-myc--antagonists & inhibitors<br/>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization<br/>Thiazoles--pharmacokinetics<br/>Tissue Distribution<br/>Treatment Outcome<br/>Tumor Cells, Cultured<br/>Xenograft Model Antitumor Assays